HARMONIC: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Condition: Non-Small Cell Lung Cancer
Sponsor: Lantern Pharma Inc.
LTRN300-2LC01-OR21: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors (HARMONIC)
Study for never smoker patients with an advanced or metastatic lung adenocarcinoma that have previously been treated with targeted therapy for an actionable genomic alteration.
Participants will be randomized 2:1 to receive one of the following treatment regimens:
Arm A: LP-300 + carboplatin + pemetrexed
Arm B: carboplatin + pemetrexed
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.